quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:23:29·56d
PRRelease
SCYNEXIS Inc. logo

SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247

SCYX· SCYNEXIS Inc.
Health Care
Original source

Companies

  • SCYX
    SCYNEXIS Inc.
    Health Care

Related

  • SEC3d
    SEC Form PRE 14A filed by SCYNEXIS Inc.
  • SEC3d
    SCYNEXIS Inc. filed SEC Form 8-K: Leadership Update
  • SEC6d
    SEC Form PRE 14A filed by SCYNEXIS Inc.
  • INSIDER21d
    SEC Form 4 filed by Angulo Gonzalez David
  • SEC23d
    SCYNEXIS Inc. filed SEC Form 8-K: Regulation FD Disclosure
  • PR23d
    Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
  • SEC23d
    SCYNEXIS Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure
  • SEC23d
    SCYNEXIS Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022